Mixed neuronal-glial tumor

Mixed neuronal-glial tumors are a group of rare central nervous system (CNS) neoplasms composed of both neuronal and glial cell components. This category includes several distinct tumor types, most notably ganglioglioma, desmoplastic infantile ganglioglioma, dysembryoplastic neuroepithelial tumor (DNET), and rosette-forming glioneuronal tumor, among others. These tumors primarily affect the brain, with the cerebral cortex and temporal lobe being the most common locations, though they can occur in other CNS regions including the cerebellum, brainstem, and spinal cord. Clinical presentation varies depending on tumor location and size. The most common symptom is epilepsy, particularly drug-resistant seizures, which may be present for years before diagnosis. Other symptoms can include headaches, focal neurological deficits, increased intracranial pressure, cognitive difficulties, and visual disturbances. Many mixed neuronal-glial tumors are classified as low-grade (WHO grade I or II) and tend to have a relatively favorable prognosis, though higher-grade variants with more aggressive behavior do exist. The primary treatment approach is surgical resection, which can be curative when gross total removal is achieved. Complete resection is associated with excellent long-term outcomes and significant improvement in seizure control. For cases where complete resection is not feasible, or in the rare instances of malignant transformation or recurrence, adjuvant therapies including radiation therapy and chemotherapy may be considered. Ongoing research into the molecular characteristics of these tumors, including BRAF V600E mutations found in a subset of gangliogliomas, is opening potential avenues for targeted therapies.

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Common questions about Mixed neuronal-glial tumor